Latvija - latviešu - Zāļu valsts aģentūra

sopharma ad, bulgaria - natrii chloridum - Šķīdums injekcijām - 9 mg/ml

Latvija - latviešu - Zāļu valsts aģentūra

unimed pharma spol. s r.o., slovakia - olopatadīns - acu pilieni, šķīdums - 1 mg/ml

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol - astma - zāles obstruktīvu elpceļu slimību, - budesonide / formoterol teva pharma b. ir indicēts tikai pieaugušajiem no 18 gadu vecuma. asthmabudesonide/formoterol teva pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogrela hidrohlorīds - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiskie līdzekļi - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Latvija - latviešu - Zāļu valsts aģentūra

pharmaceutical works polpharma sa, poland - atorvastatīns - apvalkotās tabletes - 40 mg

Latvija - latviešu - Zāļu valsts aģentūra

pharmaceutical works polpharma sa, poland - atorvastatīns - apvalkotās tabletes - 20 mg

Latvija - latviešu - Zāļu valsts aģentūra

pharmaceutical works polpharma sa, poland - atorvastatīns - apvalkotās tabletes - 10 mg

Latvija - latviešu - Zāļu valsts aģentūra

pharmaswiss ceska republika s.r.o., czech republic - enalaprili maleas, lercanidipini hydrochloridum - apvalkotās tabletes - 10 mg/10 mg

Latvija - latviešu - Zāļu valsts aģentūra

pharmaswiss ceska republika s.r.o., czech republic - enalaprili maleas, lercanidipini hydrochloridum - apvalkotās tabletes - 20 mg/10 mg

Latvija - latviešu - Zāļu valsts aģentūra

g.l. pharma gmbh, austria - buprenorfīns - tablete lietošanai zem mēles - 8 mg